CN120731207A - 6-烷氧基吡唑并嘧啶化合物及其药学用途 - Google Patents

6-烷氧基吡唑并嘧啶化合物及其药学用途

Info

Publication number
CN120731207A
CN120731207A CN202480013810.2A CN202480013810A CN120731207A CN 120731207 A CN120731207 A CN 120731207A CN 202480013810 A CN202480013810 A CN 202480013810A CN 120731207 A CN120731207 A CN 120731207A
Authority
CN
China
Prior art keywords
disease
syndrome
alkyl
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480013810.2A
Other languages
English (en)
Chinese (zh)
Inventor
大场雄介
足达馨
樱井健太朗
西丸达也
生越洋介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CN120731207A publication Critical patent/CN120731207A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202480013810.2A 2023-02-24 2024-02-22 6-烷氧基吡唑并嘧啶化合物及其药学用途 Pending CN120731207A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023027437 2023-02-24
JP2023-027437 2023-02-24
PCT/JP2024/006429 WO2024177126A1 (ja) 2023-02-24 2024-02-22 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
CN120731207A true CN120731207A (zh) 2025-09-30

Family

ID=92501358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480013810.2A Pending CN120731207A (zh) 2023-02-24 2024-02-22 6-烷氧基吡唑并嘧啶化合物及其药学用途

Country Status (4)

Country Link
EP (1) EP4671246A1 (https=)
JP (2) JP7729000B2 (https=)
CN (1) CN120731207A (https=)
WO (1) WO2024177126A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140708A1 (zh) * 2023-12-31 2025-07-03 杭州百新生物医药科技有限公司 吡唑并嘧啶类化合物及其医药用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191679T1 (hr) * 2013-10-30 2019-12-13 Shanghai hengrui pharmaceutical co ltd Derivati pirazolopirimidona ili pirolotriazona, postupak pripreme jednakih i njihove farmaceutske uporabe
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2020150114A1 (en) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
US12391675B2 (en) * 2019-01-14 2025-08-19 Innate Tumor Immunity, Inc. NLRP3 modulators
CN114829345A (zh) * 2019-12-27 2022-07-29 日本烟草产业株式会社 酰基磺酰胺化合物及其医药用途
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
CA3229401A1 (en) * 2021-08-31 2023-03-09 Japan Tobacco Inc. 6-aminopyrazolopyrimidine compounds and medical use thereof
US20250114361A1 (en) * 2022-08-29 2025-04-10 Japan Tobacco Inc. Pyrazolopyrimidine compound and pharmaceutical use thereof

Also Published As

Publication number Publication date
JP7729000B2 (ja) 2025-08-25
EP4671246A1 (en) 2025-12-31
WO2024177126A1 (ja) 2024-08-29
JP2025169332A (ja) 2025-11-12
JPWO2024177126A1 (https=) 2024-08-29

Similar Documents

Publication Publication Date Title
JP7483810B2 (ja) ６－アミノピラゾロピリミジン化合物及びその医薬用途
JP7585409B2 (ja) ピラゾロピリミジン化合物及びその医薬用途
JP7729000B2 (ja) ６－アルコキシピラゾロピリミジン化合物及びその医薬用途
JP2013507364A (ja) 新規なｔｒｐａ１アンタゴニスト
JP7737490B2 (ja) 置換ピラゾロピリミジン化合物及びその医薬用途
EP3831821A1 (en) Compound for treating nervous system diseases and use thereof
KR20180085814A (ko) 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
CN119365474A (zh) Stat3抑制剂的前药
HK1204622A1 (en) (2-heteroarylamino)succinic acid derivative
HK40128856A (en) Pyrazolopyrimidine compound and pharmaceutical use thereof
CN117881682A (zh) 6-氨基吡唑并嘧啶化合物及其医药用途
HK40112889A (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
US20250333393A1 (en) Heterocyclic compound as tyk2 inhibitor, and synthesis and use thereof
CN119264114A (zh) 一种nlrp3抑制剂及其制备方法和应用
CN117903092A (zh) 二羟基苯酞类化合物及其制备方法和用途
JP2014101340A (ja) ２−アリールヒドラゾノチアゾリジン−４−オン誘導体を有効成分とするｍｋ２阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination